Neoadjuvant therapy in resectable and borderline resectable pancreatic cancer-safe but standard of care?

In fact, per-protocol analysis showed a trend toward worse overall survival with neoadjuvant therapy [hazard ratio 1.46; 95% confidence interval (CI), 0.99–2.17; log-rank P=0.058], although only 60% of patients completed all four planned cycles of neoadjuvant therapy.

also in 53,322 other papers